Retatrutide and the Meaning of an Investigational Medicine
As of November 6, 2026, retatrutide remains investigational in the United States. Published trial findings and regulatory approval are different milestones.
As of November 6, 2026, retatrutide remains investigational in the United States. Published trial findings and regulatory approval are different milestones.
The terms single, dual and triple refer to the number of receptor targets. Semaglutide targets GLP-1, tirzepatide targets GLP-1 and GIP, and retatrutide targets GLP-1, GIP and glucagon.
Glucagon receptor activity distinguishes retatrutide’s target profile from that of tirzepatide and semaglutide. Research on the combined profile includes effects on body weight and metabolic measures.
Start with the original trial paper or registered study record. Identify the intervention, comparator, population, follow-up and statistical analysis before quoting an outcome.
Nested Phase 3 sleep-apnea trials assessed change in the apnea–hypopnea index. This index counts breathing interruptions or reductions per hour of sleep.
TRIUMPH-4 enrolled participants with obesity or overweight and knee osteoarthritis. The design assessed body weight and knee symptoms within the same research program.
A 48-week study and an 80-week study measure outcomes over different periods. Enrollment, baseline characteristics, comparator conditions and analytical methods can also differ.
TRIUMPH-5 is registered as NCT06662383. Its direct comparison tests both treatments in adults with obesity using a shared trial protocol.
TRIUMPH-1, SURMOUNT-1 and STEP 1 are placebo-controlled studies of different interventions. Their published figures belong to their own populations, regimens, follow-up and analyses.
In SURMOUNT-5, adults with obesity without diabetes were randomized to tirzepatide or semaglutide. At 72 weeks the estimated mean weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide.